Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1011 | Complex diagnostic panel Wiki | 1.00 |
| drug3287 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and above and .
Description: Occurrence of adverse reactions post vaccination
Measure: Safety indexes of adverse reactions Time: within 14 days post each vaccinationDescription: Evaluate the Geometric mean titer (GMT) of IgG antibody
Measure: Immunogencity indexes of GMT Time: Day 28 post the second vaccinationDescription: Evaluate the Geometric mean titer (GMT) of neutralizing antibody
Measure: Immunogencity indexes of neutralizing antibody Time: Day 28 post the second vaccinationDescription: Occurrence of adverse reactions post-vaccination
Measure: Safety indexes of adverse events Time: Day 0-7,0-14,0-28 post each vaccinationDescription: Occurrence of abnormal changes of Hematological examination indexes(only fit for MID and sentinel group)
Measure: Safety indexes of Hematological examination measures Time: pre-vaccination, day 4 post each vaccinationDescription: Occurrence of abnormal changes of lBlood routine indexes (only fit for MID and sentinel group)
Measure: Safety indexes of Blood routine measures Time: pre-vaccination, day 4 post each vaccinationDescription: Occurrence of serious adverse events post-vaccination
Measure: Safety indexes of SAE Time: Within 6 months post the second vaccinationDescription: Evaluate the Geometric mean titer of IgG antibody
Measure: Immunogencity indexes of GMT Time: Day 28 post the first vaccination, pre the second vaccination ,Month 6 post the second vaccinationDescription: Evaluate the Geometric mean titer (GMT) of neutralizing antibody
Measure: Immunogencity indexes of neutralizing antibody Time: Day 28 post the first vaccination, pre the second vaccination ,Month 6 post the second vaccinationDescription: Number of cell-mediated immune response against SARS-CoV-2（IL-2）
Measure: Immunogencity indexes of cellular immune Time: Day 28 post the first vaccination, pre and day 28 post the second vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports